AC Immune SA (ACIU): Price and Financial Metrics
ACIU Price/Volume Stats
| Current price | $2.90 | 52-week high | $3.83 |
| Prev. close | $3.00 | 52-week low | $1.68 |
| Day low | $2.85 | Volume | 22,764 |
| Day high | $3.07 | Avg. volume | 416,003 |
| 50-day MA | $3.06 | Dividend yield | N/A |
| 200-day MA | $2.47 | Market Cap | 242.50M |
ACIU Stock Price Chart Interactive Chart >
ACIU POWR Grades
- Sentiment is the dimension where ACIU ranks best; there it ranks ahead of 75.39% of US stocks.
- ACIU's strongest trending metric is Value; it's been moving down over the last 178 days.
- ACIU's current lowest rank is in the Quality metric (where it is better than 2.7% of US stocks).
ACIU Stock Summary
- Of note is the ratio of AC IMMUNE SA's sales and general administrative expense to its total operating expenses; merely 8.61% of US stocks have a lower such ratio.
- ACIU's price/sales ratio is 54.66; that's higher than the P/S ratio of 96.47% of US stocks.
- ACIU's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 8.3% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to AC IMMUNE SA are STTK, PNT, GRTS, SYBX, and IVA.
- Visit ACIU's SEC page to see the company's official filings. To visit the company's web site, go to www.acimmune.com.
ACIU Price Target
For more insight on analysts targets of ACIU, see our ACIU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.23 | Average Broker Recommendation | 1.17 (Strong Buy) |
AC Immune SA (ACIU) Company Bio
AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by mis-folding proteins. The company was founded in 2003 and is based in Lausanne, Switzerland.
Latest ACIU News From Around the Web
Below are the latest news stories about AC IMMUNE SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue EstimatesAC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateAC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer’s disease (AD)Enrollment in ongoing Phase 1b/2 ABATE study of ACI-24.060 in AD and Down syndrome (DS) is on track and expanding to sites in USA following IND clearance, dosed first individual with DSNext interim safety and immunogenicity data from AD and DS cohorts in ABATE expected in H2 2023R |
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a Fireside chat and one-on-one investor meetings during the BTIG Virtual Biotechnology Conference 2023, taking place on August 7-8, 2023. During the Fireside chat, Dr. Andrea Pfeifer, CEO of AC Im |
AC Immune SA Appoints New Chief Medical OfficerAC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment of Nuno Mendonça, MD. He will join the Company on October 1st, as Chief Medical Officer and be appointed to the Executive Committee. Johannes Streffer, MD, curren |
AC Immune Showcasing Precision Medicine Programs at AAIC 2023AC Immune Showcasing Precision Medicine Programs at AAIC 2023 Lausanne, Switzerland, July 3, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at the annual Alzheimer’s Association International Conference (AAIC 2023), taking place in Amsterdam, The Netherlands, on July 16-20, 2023. The presentations will include a poster detailing the design of the Phase 1b/2 ABATE t |
ACIU Price Returns
| 1-mo | -6.75% |
| 3-mo | -1.86% |
| 6-mo | 23.93% |
| 1-year | -7.05% |
| 3-year | -39.33% |
| 5-year | -63.75% |
| YTD | 42.16% |
| 2022 | -58.79% |
| 2021 | -4.26% |
| 2020 | -39.32% |
| 2019 | -9.84% |
| 2018 | -26.17% |
Continue Researching ACIU
Want to see what other sources are saying about AC Immune SA's financials and stock price? Try the links below:AC Immune SA (ACIU) Stock Price | Nasdaq
AC Immune SA (ACIU) Stock Quote, History and News - Yahoo Finance
AC Immune SA (ACIU) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...